SCHEMBL2969958

SCHEMBL2969958

NC(=O)CNS(=O)(=O)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 4/20 0.59
MMP12 P39900 2/20 0.59
GAA P10253 1/20 0.59
ALDH1A1 P00352 4/20 0.55
MMP2 P08253 3/20 0.54
MMP13 P45452 3/20 0.54
MMP9 P14780 2/20 0.54
MMP8 P22894 2/20 0.54
MMP14 P50281 2/20 0.54
MEP1B Q16820 2/20 0.54
MMP3 P08254 1/20 0.54
MMP7 P09237 1/20 0.54
ADAM17 P78536 1/20 0.54
KEAP1 Q14145 1/20 0.53
KDM4E B2RXH2 1/20 0.53
LMNA P02545 1/20 0.53
PKM P14618 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
PRMT1 Q99873 1/20 0.53
TBXA2R P21731 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6848814 0.90 MMP1 (0.76) MMP1MMP12GAAMMP2MMP13
SCHEMBL359770 0.84 MMP1 (0.79) MMP1MMP12GAAALDH1A1MMP2
SCHEMBL2760714 0.84 MMP1 (0.61) MMP1MMP12GAAALDH1A1MMP2
SCHEMBL13723973 0.83 CA1 (0.65) MMP1ALDH1A1MMP2MMP13MMP9
SCHEMBL19667212 0.82 MEP1B (0.72) MEP1BKMT2ACA1CA2
SCHEMBL6848886 0.82 MEP1B (0.56) MMP1ALDH1A1MMP2MMP13MMP14
SCHEMBL4859251 0.81 ALDH1A1 (0.61) MMP1ALDH1A1MMP2MMP13MMP9
SCHEMBL20743688 0.81 MMP1 (0.66) MMP1MMP12GAAMMP2MMP13
SCHEMBL6850069 0.81 MEP1B (0.62) MMP1GAAALDH1A1MMP2MMP13
SCHEMBL6850445 0.81 MEP1B (0.62) MMP1ALDH1A1MMP2MMP13MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1853573-A1 BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION Rigel Pharmaceuticals, Inc. (US) 2007-11-14 EP claimed
WO-2006091858-A1 BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION RIGEL PHARMACEUTICALS, INC. (US) 2006-08-31 WO claimed
US-20240399776-A1 COLOR DEVELOPER, THERMAL RECORDING MATERIAL, AND THERMAL RECORDING LAYER COATING MATERIAL SANKO CO., LTD. (JP) 2024-12-05 US disclosed
EP-4269119-A1 COLOR DEVELOPER, HEAT-SENSITIVE RECORDING MATERIAL, AND COATING MATERIAL FOR HEAT-SENSITIVE RECORDING LAYERS Sanko Co., Ltd. (JP) 2023-11-01 EP disclosed
US-20210032265-A1 COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-02-04 US disclosed
US-9949980-B2 Drugs to prevent HPV infection WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2018-04-24 US disclosed
EP-2462141-B1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2017-09-27 EP disclosed
US-20150297602-A1 DRUGS TO PREVENT HPV INFECTION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-22 US disclosed
US-9066951-B2 Drugs to treat HPV infection WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2015-06-30 US disclosed
US-9023847-B2 Azaheterocyclic compounds MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
CN-103261176-A 1, 4-oxazepane derivatives TAKAEDA CHEMICAL IND LTD 2013-08-21 CN disclosed
CN-1106982-A Maillard reaction inhibitor OTSUKA PHARMA CO LTD (JP) 1995-08-16 CN disclosed
US-RE29668-E 4-OXO-1,2-BENZOTHIAZINE-3-CARBOXAMIDE, 1,1-DIOXIDES, ANTIINFLAMMATORY PFIZER INC. (US) 1978-06-13 US disclosed
US-RE29669-E CYCLIZATION OF GLYCINEAMIDES PFIZER, INC. (US) 1978-06-13 US disclosed
US-4076722-A Composition containing alkyl 2-{[({[(5-methyl-3-isoxazolyl)-amino]carbonyl}methyl)amino]sulfonyl}benzoate and an alkali metal alkoxide of a lower alcohol in an inert solvent WARNER-LAMBERT COMPANY (US) 1978-02-28 US disclosed
US-4076722-A Composition containing alkyl 2-{[({[(5-methyl-3-isoxazolyl)-amino]carbonyl}methyl)amino]sulfonyl}benzoate and an alkali metal alkoxide of a lower alcohol in an inert solvent WARNER-LAMBERT COMPANY (US) 1978-02-28 US disclosed
US-3987038-A Process for the preparation of {1-[5-(4-hydroxy-2H-1,2-benzothiazin-3-yl)-1,2,4-oxadiazol-3-yl]methyl}ethanone S,S-dioxide WARNER-LAMBERT COMPANY (US) 1976-10-19 US disclosed
US-3987038-A Process for the preparation of {1-[5-(4-hydroxy-2H-1,2-benzothiazin-3-yl)-1,2,4-oxadiazol-3-yl]methyl}ethanone S,S-dioxide WARNER-LAMBERT COMPANY (US) 1976-10-19 US disclosed
US-3971802-A ANTIINFLAMMATORY PFIZER INC. (US) 1976-07-27 US disclosed
US-3954786-A ANTIINFLAMMATORY AGENTS PFIZER INC. (US) 1976-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150297602-A1 DRUGS TO PREVENT HPV INFECTION VHL, PHF13, CDKN1A MMP1 1629/4885MMP12 311/4885GAA 4161/4885
US-20210032265-A1 COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY PTGS1, HPGD, PTGIS MMP1 404/4885MMP12 256/4885GAA 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.